Courtesy of Dr. Carlos Fava. Repairing the mitral valve with Mitraclip has become an alternative for high risk or inoperable symptomatic patients, but its long term evolution has only been tested by the EVEREST II, which had not taken into account 5 year mortality outcomes. Therefore, to better study its evolution, we need to carry out different randomized studies...
Current surgical and medical treatment options for severe tricuspid regurgitation are extremely limited. However, this historically forgotten valve seems to have the option of transcatheter repair, nowadays. This observational study assessed the safety and feasibility of the MitraClip system for patients with severe chronic tricuspid regurgitation. All patients presented severe tricuspid regurgitation and...
Courtesy of Dr. Carlos Fava. The association between diastolic dysfunction (DD) and aortic insufficiency (AI) after transcatheter aortic valve replacement (TAVR) has not been studied yet, but the presence of aortic regurgitation has proved to be associated with worse outcomes. A total of 144 out of 195 patients who underwent TAVR with balloon-expandable SAPIENS or SAPIENS XT...
Courtesy of Dr. Carlos Fava. Atrial fibrillation (AF) and fast heart rate (>70 lpm) have been shown to increase the risk of mitral valve repair surgery. The MitraClip has shown benefits in high risk patients, but its relation to abnormal heart rhythm has not yet been established. 760 patients were analyzed; 315 (52.4%) presented...
We thank all the speakers of the Chile 2016 Sessions who shared their presentations to contribute to our mission of promoting the dissemination of information from research and clinical practice in Interventional Cardiology. You can read and/or download them below Lluberas, Ricardo. “Role of pharmacovasive therapy in the treatment of IAMcEST. Implications for Latin...
Courtesy of Dr. Carlos Fava. Patients with severe mitral regurgitation unfit for surgery due to high surgical risk are likely to develop chronic kidney disease (CKD). There is limited information available on patients with CKD receiving MitraClip. This study analyzed patients receiving MitraClip and presenting chronic kidney disease. CKD was defined as a...
Original Title: Randomized Comparison of Percutaneous Repair and Surgery for Mitral Regurgitation. 5 – Years Results of EVEREST II. Reference: Ted Feldman et al. J Am Coll Cardiol 2015;66:2844-54 Courtesy of Dr. Carlos Fava The MitraClip at 12 months in the EVEREST II trial showed similar outcomes to that of surgery, with improved ventricular remodeling and...
Original title: Impact of chronic kidney disease on the outcome of transcatheter aortic valve implantation: results from the FRANCE 2 Registry. Reference: Atsushi Oguri, et al. EuroIntervention 2015;10:e1-9 Globally, 13% of patients present kidney failure, which has been associated to a worse evolution not only of TAVI outcomes but also of other cardiovascular intervention outcomes. Most studies, including...
Original title: Percutaneous Mitral Valve Repair for Mitral Regurgitation in High-Risk Patients. Results of the EVEREST II Study. Reference: Donald D. Glower et al. J Am Coll Cardiol 2014;64:172-81 Severe mitral regurgitation (MR) often lead to hospitalization for cardiac failure and heart surgery. Half of these patients are rejected for high surgical risk. Percutaneous intervention is a valid...
Original title: Determinats and Outcomes of Acute transcatheter Valve-in Valve Therapy or Embolization. Reference: Raj R Makkar, et al. J Am Coll Cardiol 2013;62:418-30 Percutaneous aortic valve implantation has proven to be feasible, safe and a successful follow up. Only in a few patients is the two-valve implantation necessary due to bad positioning or embolism but...